Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19

 Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19

Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19

Shots:

  • The FDA authorized EUA for bamlanivimab (700 mg) and etesevimab (1400 mg) for the treatment of mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
  • The EUA is based on P-III BLAZE-1 trial in ≥1,000 COVID-19 patients showed 70% reduction in hospitalizations. Lilly plans to manufacture 250,000+ doses in Q1’ 21 and up to 1M doses by mid-2021
  • The FDA authorizes new protocols for infusion of bamlanivimab as monothx. and bamlanivimab and etesevimab together in as few as 16 and 21 min respectively

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Genetic Engineering and Biotechnology News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post